Revolution Medicines
Prix: 153.87Entreprise et modèle économique
Revolution Medicines is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases. Its core products include small molecule inhibitors designed to address specific genetic mutations in tumors. The company operates primarily in the healthcare sector, with major revenue sources stemming from partnerships, collaborations, and potential future product sales.
Profil d’investissement
The investment profile of Revolution Medicines may appeal more to growth investors due to its focus on innovative therapies and potential for future revenue generation. However, the high risk associated with its current financial performance and lack of profitability suggests caution. The stock may not be suitable for dividend or value investors at this time.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -7.11 Risque
- Surprise BPA
- -25.1% moins bon que prévu
- Volatilité 20 j
- 2.8% stable
Impact de la prévision
neutreSuivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-03 02:51 | Conserver | Vendre | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-22 02:58 | Vendre | Conserver | High growth but significant losses and uncertainty remain. |
| 2026-05-08 14:57 | — | Vendre | Weak fundamentals and negative momentum raise significant risk. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-09 13:24 | UBS | Mettre à jour | — → 175 | 148.4461 |
| 2026-06-02 09:03 | RBC Capital | Objectif relevé | — → 182 | 163.68 |
| 2026-06-01 14:33 | H.C. Wainwright | Objectif relevé | 169 → 195 | 162.51 |
Rien pour le moment